To investigate the effectiveness and safety of the homeopathic product SilAtro-5-90 in recurrent tonsillitis. In this international, pragmatic, controlled clinical trial, 256 patients (6-60 years) with moderate recurrent tonsillitis were randomized to receive either SilAtro-5-90 in addition to standard symptomatic treatment, or to receive standard treatment only. The primary outcome was the mean time period between consecutive acute throat infections (ATI) within 1 year (analyzed via repeated events analysis). During the evaluation year, the risk of getting an ATI was significantly lower (hazard ratio: 0.45, proportional means model, p = 0.0002, ITT) with SilAtro-5-90 compared to control. Tonsillitis-specific symptoms were significantly reduced (p < 0.0001, ITT) and the need of antibiotics to treat acute throat infections (p = 0.0008; ITT) decreased. 3 non-serious adverse drug reactions were reported for SilAtro-5-90. An integrative treatment approach where SilAtro-5-90 is given alongside mainstream symptomatic treatment may bring therapeutic benefit to patients suffering from recurrent tonsillitis. ISRCTN registry: Registration number ISRCTN19016626, registered 23 January 2013.
Aim: Insufficient or poor sleep quality in children may have a major impact on the whole family. Homeopathy may offer a safe treatment option. In an open, multicenter, randomized, controlled trial the effectiveness of the homeopathic complex medication ZinCyp-3-02 (Dormikind®: cypripedium pubescens D4, magnesium carbonicum D10 and zincum valerianicum D12) was investigated in pediatric sleep disorders. Methods: Children (0 – 6 years) with sleep disorders for = 1 month received either ZinCyp-3-02 or Glycine tablets (control) for 28 days. Total score of five sleep related complaints + physical inactivity + restlessness (TSC, maximum 11 points), variances of the 7 individual complaints, satisfaction and incidence of adverse drug reactions (ADRs) were assessed by parents and/or investigators. Results: In the 179 children (ZinCyp-3-02: N = 89, control: N = 90) included and analyzed, TSC decreased from baseline to Termination Visit (ZinCyp-3-02: median 7.0 → 2.0; control: median 7.0 → 4.0) with significantly higher odds of showing lower TSC (Odds Ratio: 4.45 (95%-CI: 2.77 – 7.14), p < 0.0001; ITT) in the children with ZinCyp-3-02 treatment for 28 days. First clinical effects were seen already after 14 days, absence of individual complaints was demonstrated in significantly more ZinCyp-3-02 children (Chi2-test: all P values = 0.0475; ITT) at the study end. Significantly more very satisfied and satisfied ratings were obtained by the parents of the ZinCyp-3-02 group (N = 82 vs. N = 38; Chi2-test: p < 0.0001; ITT) and only few ADRs occurred (ZinCyp-3-02: N = 2 (nervousness, excitability); control: N = 1 (excitement)). Conclusions: ZinCyp-302 tablets in the test group showed to be superior compared to the control group, was safe in use and parents were satisfied with the treatment of their children.
21 March 2017 in Allgemeine Homöopathische Zeitung